Abexinostat (PCI-24781)

目录号:S1090 别名: CRA-024781

Abexinostat (PCI-24781) Chemical Structure

Molecular Weight(MW): 397.42

Abexinostat (PCI-24781)是一种新型的pan-HDAC抑制剂,靶向作用于HDAC1Ki为7 nM,对HDACs 2, 3, 6,和10有适中的抑制性,但比作用于HDAC8选择性强40倍。Phase 1/2。

规格 价格 库存 购买数量  
RMB 2217.61 现货
RMB 1406.39 现货
RMB 2628.91 现货
RMB 7938.64 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用该产品的3个实验数据:

  • Differential effects of HDAC inhibitors on histone and tubulin acetylation. Immunofluorescence analysis of histone H3 (K9ac/K14ac) and tubulin acetylation in HeLa cells treated for 4 h with vehicle, SAHA (10 μM), tacedinaline (50 μM), PCI-24781 (20 μM. (a) Mapping of histone acetylation in K562 cells treated with HDAC inhibitors by LC-MS/MS. Cells were treated with TSA (10 μM), SAHA (5 μM), PCI-24781 (2 μM), tacedinaline (50 μM) for 6 h. Histones were extracted from cells and acetylated peptides were quantified after isobaric tagging.

    Nat Biotechnol 2011 29, 255-265. Abexinostat (PCI-24781) purchased from Selleck.

    Class I selective HDACi have the highest INS-1 rescue potential . INS-1 cells were monitored using the real-time xCELLigence system h and the impedance (cell adhesion) was measured as a surrogate of cell viability (cell index) as described in the Methods. (a ) The impedance of duplicates of control (green line), cytokine-exposed (red line) and cytokine+ITF-J-exposed INS-1 cells (blue line) was followed from the start of exposure (indicated by the arrow). Heat maps of 13 different ITF HDAC inhibitor compounds ( b )orsix different commercial HDAC inhibitor compounds (c) were made based on their IC50 values towards selected HDACs . The HDACi inhibitors are ranked after rescue potential according to ESM Tables 1, 2 .( c) Values are corrected for differences in potency since they varied from 33.3 (CI-994) to 0.041 (LAQ824). (d ) Colour code for both heat maps: low IC50 values coloured red, intermediate IC50 values coloured black and high IC50 values coloured blue; grey indicates undetermined IC50.

    Biochem Bioph Res Co 2012 55, 2421-31. Abexinostat (PCI-24781) purchased from Selleck.

  • Analyses of efficacy, potency and IC50 of HDAC inhibitors point toward HDACs 1–3 as relevant candidates for beta cell protection. Ranking and raw data on ITF drugs (Table 3) and commercial HDAC inhibitors (Table 4) underlying the heat maps of Fig. 1 (A and B). The HDAC inhibitor compounds were tested using a HDAC activity kit and recombinant proteins to determine IC50 values on each individual HDAC (right part of the table). Each drug was further tested using Real-Time Cell Analysis (RTCA) to score their maximal effective concentration (ECmax) as well as the corresponding rescue percentage of cytokine treated INS-1 cells. The drugs were ranked according to % rescue. * DMSO alone controls were included in each experiment, but not shown here. The results indicate that the highest concentrations of DMSO used here (1:1,000) were slightly potentiating the proliferation of the cells. The effects observed in this group of compounds were ascribed to the DMSO.?

    Biochem Bioph Res Co 2011 414, 25-30. Abexinostat (PCI-24781) purchased from Selleck.

产品安全说明书

HDAC抑制剂选择性比较

生物活性

产品描述 Abexinostat (PCI-24781)是一种新型的pan-HDAC抑制剂,靶向作用于HDAC1Ki为7 nM,对HDACs 2, 3, 6,和10有适中的抑制性,但比作用于HDAC8选择性强40倍。Phase 1/2。
靶点
HDAC1 [1]
(Cell-free assay)
HDAC3/SMRT [1] HDAC6 [1] HDAC2 [1]
(Cell-free assay)
HDAC10 [1]
7 nM(Ki) 8.2 nM(Ki) 17 nM(Ki) 19 nM(Ki) 24 nM
体外研究

PCI-24781针对于多种肿瘤细胞系具有有效的抗肿瘤活性,GI50分布于0.15 μM 到3.09 μM之间。PCI-24781也抑制HUVEC 内皮细胞的增值,GI50为0.43 μM。PCI-24781处理导致HCT116 和 DLD-1细胞系中组蛋白乙酰化和微管蛋白乙酰化的剂量依赖性积累,同时诱导p21表达,PARP的剪切以及γH2AX的累积[1]。PCI-24781抑制HDACs酶活导致HR 相关基因的转录水平出现明显下降,其中包括RAD51。与抑制HR 一致,在CHO细胞中,PCI-24781处理后导致I-SceI诱导染色质断裂引起的同源定向修复能力下降[2]。PCI-24781诱发S 期缺失,G2期细胞周期停滞以及软组织(STS)细胞的凋亡。PCI-24781诱导STS细胞中Rad51 的转录抑制很有可能是通过增强E2F1在Rad51近端启动子区域的结合[3]。PCI-24781也诱导Hodgkin淋巴瘤和非霍奇金淋巴瘤中蛋白酶和活性氧依赖的NF-κB信号通路介导的细胞凋亡过程[4]

体内研究 PCI-24781按200 mg/kg 剂量作用于移植小鼠,隔一天一次,明显抑制HCT116 和 DLD-1肿瘤细胞生长,抑制效果分别是69%和59%。PCI-24781按20 mg/kg, 40 mg/kg, 80 mg/kg和160 mg/kg剂量每星期连续四天给药处理,然后三天不给药处理((一天一次,每周四天))作用于HCT116移植小鼠模型,抑制效果分别是48%, 57%, 82.2%, 和80.0%[1]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:[1]
+ 展开

HDAC 酶活鉴定:

运用连续胰蛋白酶耦合分析法检测HDAC酶活。将100μL反应体系置于96孔板中分析抑制剂表征。将HDAC 酶添加到50 mM HEPES, 100 mM KCl, 0.001% Tween 20, 5% DMSO (pH 7.4) 以及补充了牛血清蛋白 (BSA)的反应体系中,与不同浓度的PCI-24781混合均匀,孵育15分钟。每种HDAC同工酶使用的BSA浓度不一样,分别是0% (HDAC1),0.01% (HDAC2, 3, 8, 10)和0.05% (HDAC6)。胰蛋白酶的终浓度是50 nM,acetyl-Gly-Ala-(N-acetyl-Lys)-AMC的终浓度是25μM(HDAC1,HDAC3,HDAC6),50μM (HDAC2,HDAC10)和100 μM (HDAC8),起始反应。设置八个复孔的阴性对照中不加入PCI-24781。使用酶标仪检测反应。经过30分钟的延迟时间,通过355纳米的激发波和460纳米吸收波得到荧光值。检测反应速率是测定增强荧光所需的反应时间。使用程序BatchKi可以得到抑制常数K i (app)
细胞实验:[1]
+ 展开
  • Cell lines: HCT116, HCT-15, BT-549, NCI-H226, CWR-22RV1, MCF-7, NCI-PC3, DLD-1, SKOV-3和 OVCAR-3细胞
  • Concentrations: 0–10 μM,溶于 DMSO
  • Incubation Time: 48, 72, 96和120 小时
  • Method: 运用一种微量蓝色荧光的细胞增殖试验检测PCI-24781处理后细胞增殖,细胞至少培养两倍增。细胞接种于96孔板,PCI-24781设置9个从0.0015 μM 到10 μM半对数不等间隔的浓度梯度,每一梯度设计三个复孔。DMSO终浓度每孔0.15%。设定抑制细胞增殖GI50在达到50% 到 95%之间为置信区间,运用四参数方程,利用非线性回归曲线计算PCI-24781的有效浓度。
    (Only for Reference)
动物实验:[1]
+ 展开
  • Animal Models: 携带HCT116 和DLD-1移植瘤细胞的BALB/c nu/nu 雌小鼠
  • Formulation: 配制于30% HP-cyclodextrin 水溶液中
  • Dosages: ~200 mg/kg
  • Administration: 每隔一天一次或者每星期连续四天,停滞三天。
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 80 mg/mL (201.29 mM)
Water Insoluble
Ethanol Insoluble

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 397.42
化学式

C21H23N3O5

CAS号 783355-60-2
稳定性 powder
in solvent
别名 CRA-024781

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01543763 Unknown status Metastatic Solid Tumors University of California, San Francisco|GlaxoSmithKline|Pharmacyclics LLC. May 2012 Phase 1
NCT01149668 Completed Lymphoma|Non-Hodgkins Lymphoma|Hodgkin Disease|Multiple Myeloma|Leukemia|Lymphocytic Pharmacyclics LLC. June 2010 Phase 1
NCT01027910 Completed Sarcoma Massachusetts General Hospital|Dana-Farber Cancer Institute|Brigham and Womens Hospital|Pharmacyclics LLC. February 2009 Phase 1|Phase 2
NCT00724984 Completed Lymphoma|Hodgkin Disease|Lymphoma, Non-Hodgkin Pharmacyclics LLC. July 2008 Phase 1|Phase 2
NCT00562224 Completed Neoplasms by Site|Lymphoma, Non-hodgkin|Hodgkin Disease|Multiple Myeloma|Leukemia, Lymphocytic, Chronic Pharmacyclics LLC. November 2007 Phase 1

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

相关HDAC产品

Tags: 购买Abexinostat (PCI-24781) | Abexinostat (PCI-24781)供应商 | 采购Abexinostat (PCI-24781) | Abexinostat (PCI-24781)价格 | Abexinostat (PCI-24781)生产 | 订购Abexinostat (PCI-24781) | Abexinostat (PCI-24781)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID